CSTONE PHARMACEUTICALSCSTONE PHARMACEUTICALSCSTONE PHARMACEUTICALS

CSTONE PHARMACEUTICALS

No trades
See on Supercharts
Market capitalization
‪1.16 B‬HKD
−0.32HKD
‪−405.79 M‬HKD
‪512.54 M‬HKD
‪821.76 M‬
Beta (1Y)
1.42

About CSTONE PHARMACEUTICALS

CEO
Jian Xin Yang
Headquarters
Shanghai
Employees (FY)
230
Founded
2015
ISIN
KYG2588M1006
FIGI
BBG00N9XPM92
Cstone Pharmaceuticals Co. Ltd. is an investment holding company, which engages in the research and development of complex biopharmaceutical products and sale of pharmaceutical products. Its products include immuno-oncology drugs and molecularly targeted drugs. The company was founded on December 2, 2015, and is headquartered in Shanghai, China.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 2616 is 0.90 HKD — it has decreased by 2.17% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange CSTONE PHARMACEUTICALS stocks are traded under the ticker 2616.
CSTONE PHARMACEUTICALS is going to release the next earnings report on Aug 22, 2024. Keep track of upcoming events with our Earnings Calendar.
2616 stock is 3.33% volatile and has beta coefficient of 1.42. Check out the list of the most volatile stocks — is CSTONE PHARMACEUTICALS there?
2616 earnings for the last quarter are −0.18 HKD per share, whereas the estimation was −0.31 HKD resulting in a 41.38% surprise. The estimated earnings for the next quarter are −0.11 HKD per share. See more details about CSTONE PHARMACEUTICALS earnings.
CSTONE PHARMACEUTICALS revenue for the last quarter amounts to ‪282.56 M‬ HKD despite the estimated figure of ‪384.50 M‬ HKD. In the next quarter revenue is expected to reach ‪410.82 M‬ HKD.
Yes, you can track CSTONE PHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
2616 stock has risen by 5.88% compared to the previous week, the month change is a 1.10% fall, over the last year CSTONE PHARMACEUTICALS has showed a 73.68% decrease.
2616 net income for the last quarter is ‪−170.70 M‬ HKD, while the quarter before that showed ‪−236.62 M‬ HKD of net income which accounts for 27.86% change. Track more CSTONE PHARMACEUTICALS financial stats to get the full picture.
Today CSTONE PHARMACEUTICALS has the market capitalization of ‪1.17 B‬, it has decreased by 3.49% over the last week.
No, 2616 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 2616 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CSTONE PHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.
2616 reached its all-time high on Jun 21, 2021 with the price of 19.12 HKD, and its all-time low was 0.80 HKD and was reached on Apr 5, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has 230.00 employees. See our rating of the largest employees — is CSTONE PHARMACEUTICALS on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CSTONE PHARMACEUTICALS technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CSTONE PHARMACEUTICALS stock shows the sell signal. See more of CSTONE PHARMACEUTICALS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CSTONE PHARMACEUTICALS future price: according to them, 2616 price has a max estimate of 2.92 HKD and a min estimate of 2.92 HKD. Read a more detailed CSTONE PHARMACEUTICALS forecast: see what analysts think of CSTONE PHARMACEUTICALS and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CSTONE PHARMACEUTICALS EBITDA is ‪−602.76 M‬ HKD, and current EBITDA margin is −118.01%. See more stats in CSTONE PHARMACEUTICALS financial statements.